சுமி சுகன்யா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from சுமி சுகன்யா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In சுமி சுகன்யா Today - Breaking & Trending Today
Express News Service NEW DELHI: Pune-based vaccine maker Gennova could become the second company in India to receive advance payment from the Union government for manufacturing and stockpiling its Covid-19 vaccine, based on mRNA platform, that has shown encouraging results in Phase 1 trials. Importantly, the manufacturer which is set to apply to the apex drug regulator to begin Phase 2 and 3 trials, is also tailoring the vaccine specifically against the delta variant of the Covid virus, which caused the devastating second wave in India. The Centre last month had made an advance payment of Rs 1,500 crore to Hyderabad-based vaccine maker Biological E for procuring its Covid vaccine, still under Phase 3 clinical trials, marking the first such deal. By doing this, the government secured 30 crore doses, likely to be available by December end. ....
Higher Covid vaccination may be why Delhi doing better than Mumbai As on July 23, Mumbai had 10,608 active Covid-19 cases while Delhi had only 573 coronavirus patients under treatment in hospitals or under home isolation, which is 178% less. Share Via Email | A+A A- A health worker prepares to administer the Covishield vaccine to a woman at a government hospital in Noida. (Photo | AP) NEW DELHI: The two most populous cities in India, Mumbai and Delhi, followed almost similar Covid-19 trajectories when the devastating second wave caught the country unawares, but the following weeks in these cities have thrown an epidemiological mystery with more questions than answers. ....
Centre begins inquiry into bird flu death of 11-year-old in Gurugram newindianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newindianexpress.com Daily Mail and Mail on Sunday newspapers.
Express News Service NEW DELHI: In sharp contrast to the claims of Bharat Biotech on ramping up Covaxin’s production, only about 2.8 crore of its doses had been made available for the ongoing vaccination drive till June 12. This information was part of the 380-page affidavit the Union health and family welfare ministry filed in the Supreme Court on Saturday. Of the over 32 crore vaccine doses administered so far, the share of Covishield, produced by Serum Institute of India, is more than 90%. The latest revelation on Covaxin’s low availability indicates the Hyderabad-based vaccine maker has been able to supply only about 50 lakh doses per month so far even though it has been claiming that it is constantly scaling up its manufacturing capacity and had reached 2 crore per month capacity in May. ....
Delta Plus is a potential concern: Virologist- The New Indian Express newindianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newindianexpress.com Daily Mail and Mail on Sunday newspapers.